On November 22, Sumgen Biotech reported that the "Safety, Tolerability and Preliminary Effectiveness of SG1408 for Injection in Subjects with Advanced Malignant Solid Tumors" sponsored by Zhongsheng Shangjian Biomedicine (Hangzhou) Co., Ltd. (hereinafter referred to as Zhongsheng Shangjian) Phase I clinical study of "Phase I Clinical Research Center of Zhejiang Cancer Hospital completed the first administration of the first subject (Press release, Sumgen Biotech, NOV 22, 2022, View Source;a=nav&id=293 [SID1234625273]). This is another key milestone in the clinical research of SG1408 following the successful kick-off meeting held in Zhejiang Cancer Hospital on November 3.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Ms. Li Na, clinical director and vice president of Shangjian Biology and Zhongsheng Shangjian, said that SG1408 for injection is an innovative drug targeting PD-L1/VEGF independently developed by Zhongsheng Shangjian. The Drug Administration approved clinical trials in patients with advanced solid tumors. The project can overcome the impact of the new crown epidemic and start and advance quickly. I would like to thank Secretary Cheng Xiangdong, Director Song Zhengbo of Zhejiang Cancer Hospital, leaders at all levels of the hospital, and China Biotech for their strong support, and thank the project team for their joint efforts; look forward to everyone’s joint efforts Under the circumstances, the project can make further positive progress and benefit more cancer patients.
About SG1408 Phase I Clinical Trial
PD-L1 and VEGF are important targets for tumor therapy. The SG1408 double antibody can specifically bind PD-L1 and VEGF at the same time. On the one hand, by binding to PD-L1 on the surface of tumor cells, it can specifically block the PD-1/PD-L1 immunosuppressive signaling pathway and activate the body’s immune response; On the one hand, by combining with VEGF molecules, it effectively blocks the interaction of VEGF/VEGFR, inhibits the formation of tumor angiogenesis, and inhibits the proliferation and migration of tumor cells; the two mechanisms can exert a synergistic anti-tumor effect. Preclinical studies have shown that SG1408 has a clear anti-tumor effect, can exert a synergistic effect of "1+1>2", and has good safety. At present, there are no dual-antibody drugs targeting both PD-1/PD-L1 and VEGF approved for marketing at home and abroad. SG1408, as the first double antibody project developed by Zhongsheng Shangjian, is a manifestation of the further improvement of the company’s antibody research and development system.
SG1408 phase I clinical trial population is patients with relapsed or refractory advanced malignant solid tumors, focusing on chest tumors (lung cancer, thymus cancer), gynecological tumors (cervical cancer, endometrial cancer), digestive tract tumors (liver cancer, esophageal cancer) , colorectal cancer), etc., the project has been launched in the phase I clinical center of Zhejiang Cancer Hospital, and many centers have recently started, welcome to consult for details.